Plain English Summary
Background and study aims
Ulcerative colitis (UC) is a long-term condition where the colon and rectum become inflamed. It affects over 30,000 patients in the UK and patients with long-term UC are at an increased risk of developing bowel cancer. Timely recognition of the development of cancer is vital in order to improve outcome for patients. Currently in the UK patients undergo regular and thorough surveillance of the colon to look for the early signs of cancer. Unfortunately this is not adequate and the mortality from late-detected colitis-associated cancers remains high. The main aim of this study is to evaluate the ability of a new diagnostic test to detect patients at high risk of developing colon cancer compared to histology. The test is based on determining whether certain genes that protect against the development of cancer have been inactivated and if effective, could result in a significant change in practice.
Who can participate?
This study aims to recruit up to 1000 patients across NHS hospitals in the UK that have active long-term inflammatory bowel disease endoscopic surveillance programmes. Eligible patients will have UC (either for at least 10 years with extensive disease, or also have primary sclerosing cholangitis), will be on the surveillance programme and undergoing a routine colonoscopy during the study period, have no previous history of colorectal cancer and meet the rest of the rest of the eligibility criteria.
What does the study involve?
All patients will undergo a routine surveillance colonoscopy. In addition to the routine biopsies, an additional five biopsies will be taken. If cancer or the early stages of cancer are detected, then the patient will be offered surgery. Patients for which the new test detects cancer but histology does not, will undergo a repeat colonoscopy at 4 to 12 months. Patients will be followed up through routinely collected data sources, to include, for example, cancer development and long-term survival.
What are the possible benefits and risks of participating?
There may be no direct benefit in taking part in this study, however, participants may benefit from that any pre-cancer changes will be detected early which would ensure that treatments could be started earlier. It has been shown that starting treatment earlier is often more effective. The study may involve an extra colonoscopy between 6 and 9 months after entry into the study. This will involve standard bowel preparation (including laxatives or an enema). A sedative and pain killers may also be given during the colonoscopy. The procedure will be of roughly the same duration as the initial colonoscopy. There is a very small risk (a 1 in 1000 chance) with colonoscopy of bowel perforation or bleeding. If this happened, an operation would be required to repair the hole. At the second colonoscopy you will also be asked to provide a stool sample and to collect a small blood sample.
Where is the study run from?
University of Birmingham (UK)
When is the study starting and how long is it expected to run for?
From November 2014 to May 2018
Who is funding the study?
NIHR Efficacy and Mechanism Evaluation (UK)
Who is the main contact?
Dr Steve Johnson
As of 10/02/2017: Laura Magill
Study website
Additional identifiers
EudraCT/CTIS number
IRAS number
ClinicalTrials.gov number
Protocol/serial number
17739
Study information
Scientific title
Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis (ENDCaP-C): a multicentre test accuracy study
Acronym
ENDCaP-C
Study hypothesis
The main aim of this study is to evaluate the ability of a new diagnostic test to detect patients at high risk of developing colon cancer compared to histology.
Ethics approval(s)
First MREC approval date 30/10/2014, ref: 14/LO/1842
Study design
Non-randomised; Observational; Design type: Cohort study
Primary study design
Observational
Secondary study design
Cohort study
Study setting(s)
Hospital
Study type
Diagnostic
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Topic: Gastroenterology; Subtopic: Gastroenterology; Disease: All Gastroenterology
Intervention
Current interventions as of 21/05/2018:
Colonoscopy and biopsy: patients will have five biopsy samples taken at their routine surveillance colonoscopy. Biopsy samples will be histologically analysed and methylation status will be determined.
Patients that have a positive methylation test but negative histology will undergo a second colonoscopy at 4-12 months and an additional five biopsy samples will be taken. Histology and methylation status will be determined.
A selection of patients that have a negative methylation test but negative histology will undergo a second colonoscopy at 4-12 months and five biopsy samples will be taken. Histology and methylation status will be determined.
Study Entry: Registration only
Previous interventions:
Colonoscopy and biopsy: patients will have five biopsy samples taken at their routine surveillance colonoscopy. Biopsy samples will be histologically analysed and methylation status will be determined.
Patients that have a positive methylation test but negative histology will undergo a second colonoscopy at 6 months and an additional five biopsy samples will be taken. Histology and methylation status will be determined.
Added 10/02/2017: A selection of patients that have a negative methylation test but negative histology will undergo a second colonoscopy at 6-9 months and five biopsy samples will be taken. Histology and methylation status will be determined.
Study Entry: Registration only
Intervention type
Procedure/Surgery
Primary outcome measure
Current outcome measures as of 21/05/2018:
1. The presence of dysplasia in a mucosal biopsy taken at follow up colonoscopy at 4-12 months
2. The presence of hypermethylation and dysplasia in a mucosal biopsy taken at follow up colonoscopy at 4-12 months
Previous outcome measures as of 10/02/2017:
1. The presence of dysplasia in a mucosal biopsy taken at follow up colonoscopy at 6-9 months
2. The presence of hypermethylation and dysplasia in a mucosal biopsy taken at follow up colonoscopy at 6-9 months
Previous primary outcome measures:
1. The occurrence of dysplasia in mucosal biopsies taken at follow-up colonoscopy at 4-6 months in patients demonstrating hypermethylation (the positive predictive value)
2. The ability of hypermethylation to discriminate between patients with and without dysplasia in mucosal biopsies taken at follow up colonoscopy at 4-6 months (the diagnostic odds ratio)
Secondary outcome measures
Current secondary outcome measure as of 10/02/2017:
Complications from colonoscopy
Previous outcome measures:
1. Correlation of dysplasia in mucosal biopsies with the presence of significant hypermethylation in nondysplastic biopsies taken at the same procedure
2. Correlation of dysplasia with hypermethylation in the same biopsy
3. Correlation of methylation in biopsies from initial and reference colonoscopy
4. Complications from colonoscopy
Overall study start date
13/11/2014
Overall study end date
31/05/2018
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Current inclusion criteria as of 21/05/2018:
1. Diagnosis of chronic ulcerative colitis with symptoms for over 10 years or diagnosis of primary sclerosing cholangitis (PSC)
2. On the surveillance programme and undergoing a routine colonoscopy during the study period
3. Willing to accept the possibility of an additional colonoscopy between 4 months and 12 months
4. No previous history of colorectal cancer
5. Aged 18 years or over
6. Be able and willing to provide written informed consent for the study
Previous inclusion criteria:
1. Diagnosis of chronic ulcerative colitis of over 10 years duration and disease beyond the splenic flexure or known primary sclerosing cholangitis
2. Scheduled for surveillance colonoscopy during study period
3. Willing to accept the possibility of an additional colonoscopy between 6 months and 9 months
4. No previous history of colorectal cancer
5. Aged 18 years or over
6. Be able and willing to provide written informed consent for the study
Participant type(s)
Patient
Age group
Adult
Lower age limit
18 Years
Sex
Both
Target number of participants
Planned Sample Size: 1000; UK Sample Size: 1000
Total final enrolment
818
Participant exclusion criteria
Current exclusion criteria as of 21/05/2018:
1. Patients with fulminant colitis (if not PSC)
2. Bowel obstruction
3. Patients for whom it is not possible to undergo complete colonoscopies
4. Patients with proctitis only
5. Crohn's colitis patients (if no PSC)
6. Patients with unclassified IBD (if no PSC)
7. Patients with microscopic colitis (if no PSC)
8. Unable to give written informed consent
9. Aged under 18 years
Previous exclusion criteria:
1. Patients with fulminant colitis
2. Bowel obstruction
3. Patients in whom it is not possible to do complete colonoscopies
4. Patients with proctitis only
5. Crohn's colitis patients
6. Patients with unclassified IBD
7. Patients with microscopic colitis
8. Unable to give written informed consent
9. Less than 18 years of age
Recruitment start date
13/11/2014
Recruitment end date
31/03/2017
Locations
Countries of recruitment
England, United Kingdom
Study participating centre
Queen Elizabeth Hospital Birmingham
B15 2TH
United Kingdom
Study participating centre
Heartlands Hospital
B9 5SS
United Kingdom
Study participating centre
New Cross Hospital
WV10 0QP
United Kingdom
Study participating centre
Russells Hall Hospital
DY1 2HQ
United Kingdom
Study participating centre
Manor Hospital
WS2 9PS
United Kingdom
Study participating centre
City Hospital, Birmingham
B18 7QH
United Kingdom
Study participating centre
St Mark's Hospital
HA1 3UJ
United Kingdom
Study participating centre
John Radcliffe Hospital
OX3 9DU
United Kingdom
Study participating centre
St James’s University Hospital
LS9 7TF
United Kingdom
Study participating centre
Royal Liverpool University Hospital
L7 8XP
United Kingdom
Study participating centre
Addenbrooke’s Hospital
CB2 0QQ
United Kingdom
Study participating centre
Leicester General Hospital
LE5 4PW
United Kingdom
Study participating centre
Salford Royal Hospital
M6 8HD
United Kingdom
Study participating centre
Blackpool Victoria Hospital
FY3 8NR
United Kingdom
Study participating centre
Bournemouth Royal Hospital
BH7 7DW
United Kingdom
Study participating centre
Royal United Hospital Bath
BA1 3NG
United Kingdom
Study participating centre
West Middlesex University Hospital
TW7 6AF
United Kingdom
Study participating centre
Basingstoke and North Hampshire Hospital
RG24 9NA
United Kingdom
Study participating centre
Queen Alexandra Hospital
PO6 3LY
United Kingdom
Study participating centre
St Mary's Hospital, Isle of Wight
PO30 5TG
United Kingdom
Study participating centre
Basildon University Hospital
Basildon
SS16 5NL
United Kingdom
Study participating centre
Whipps Cross University Hospital
London
E11 1NR
United Kingdom
Study participating centre
James Cook University Hospital
Middlesbrough
TS4 3BW
United Kingdom
Study participating centre
Hull Royal Infirmary
Hull
HU3 2JZ
United Kingdom
Study participating centre
Princess Alexandra Hospital
Harlow
CM20 1QX
United Kingdom
Study participating centre
North Tyneside General Hospital
North Shields
NE29 8NH
United Kingdom
Study participating centre
Darlington Memorial Hospital
Darlington
DL3 6HX
United Kingdom
Study participating centre
Kettering General Hospital
Kettering
NN16 8UZ
United Kingdom
Study participating centre
King's Mill Hospital
Sutton-in-Ashfield
NG17 4JL
United Kingdom
Study participating centre
Luton and Dunstable University Hospital
Luton
LU4 0DZ
United Kingdom
Study participating centre
St Mary's Hospital (Paddington)
London
W2 1NY
United Kingdom
Study participating centre
Queen Elizabeth Hospital (Gateshead)
Gateshead
NE9 6SX
United Kingdom
Sponsor information
Organisation
University of Birmingham
Sponsor details
Edgbaston
Birmingham
B15 2TT
England
United Kingdom
-
Researchgovernance@Contacts.bham.ac.uk
Sponsor type
University/education
Website
ROR
Funders
Funder type
Government
Funder name
NIHR Efficacy and Mechanism Evaluation; Grant Codes: EME/11/100/29
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
A final report will be submitted for publication in the NIHR Journals Library, as required by the contract for funding for the trial. It is also intended that papers on aspects of the study will be will be submitted to high-impact peer reviewed journals.
Intention to publish date
31/05/2019
Individual participant data (IPD) sharing plan
All data requests should be submitted to the Dr Laura Magill (e.l.magill@bham.ac.uk). Access to available anonymised data may be granted following review.
IPD sharing plan summary
Available on request
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 01/01/2021 | 26/01/2021 | Yes | No |
HRA research summary | 28/06/2023 | No | No |